• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cetuximab: Its role in patients unfit for cisplatin.

作者信息

De Felice Francesca, Botticelli Andrea

机构信息

Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161 Rome, Italy.

Medical Oncology Unit B, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161 Rome, Italy.

出版信息

Oral Oncol. 2022 Jan;124:105654. doi: 10.1016/j.oraloncology.2021.105654. Epub 2021 Dec 1.

DOI:10.1016/j.oraloncology.2021.105654
PMID:34864298
Abstract
摘要

相似文献

1
Cetuximab: Its role in patients unfit for cisplatin.西妥昔单抗：其在不适于使用顺铂的患者中的作用。
Oral Oncol. 2022 Jan;124:105654. doi: 10.1016/j.oraloncology.2021.105654. Epub 2021 Dec 1.
2
Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.根治性放疗联合顺铂或西妥昔单抗治疗头颈部癌患者的生存：监测、流行病学和最终结果-医疗保险分析。
Cancer. 2018 Dec 1;124(23):4486-4494. doi: 10.1002/cncr.31708. Epub 2018 Oct 17.
3
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.术后顺铂化疗联合放疗优于西妥昔单抗联合放疗和单纯放疗：奥地利头颈部癌症登记处的 AGMT 分析。
Wien Klin Wochenschr. 2021 Nov;133(21-22):1131-1136. doi: 10.1007/s00508-021-01939-3. Epub 2021 Sep 15.
4
Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.局部晚期头颈癌同步超分割放疗联合西妥昔单抗（抗表皮生长因子受体抗体）或化疗的II/III期随机对照试验
Gulf J Oncolog. 2019 May;1(30):6-12.
5
Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.多西他赛、顺铂和西妥昔单抗同步放化疗治疗局部晚期头颈部鳞状细胞癌的II期试验
Cancer Chemother Pharmacol. 2016 Jun;77(6):1315-9. doi: 10.1007/s00280-016-3052-4. Epub 2016 May 6.
6
Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700).头颈部鳞状细胞癌诱导化疗后行根治性放疗+西妥昔单抗与放化疗的 III 期随机研究：INTERCEPTOR-GONO 研究（NCT00999700）。
Oncology. 2020;98(11):763-770. doi: 10.1159/000507733. Epub 2020 Jul 6.
7
Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.西妥昔单抗联合放疗治疗铂类药物不适合的老年晚期头颈部鳞状细胞癌患者的疗效和安全性：一项回顾性研究。
Chemotherapy. 2019;64(1):48-56. doi: 10.1159/000500714. Epub 2019 Jun 26.
8
Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.一项比较西妥昔单抗联合顺铂与放化疗治疗局部晚期头颈部癌的随机 II 期临床试验中，根据人乳头瘤病毒状态和肿瘤部位的亚组分析。
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):462-472. doi: 10.1016/j.ijrobp.2016.10.011. Epub 2016 Oct 20.
9
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).avelumab-西妥昔单抗-放疗与头颈部局部晚期鳞状细胞癌的标准治疗比较：GORTEC 2017-01（REACH）随机 III 期试验的安全性阶段。
Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24.
10
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.贝伐单抗+西妥昔单抗+顺铂联合同期调强放疗用于Ⅲ/ⅣB期头颈部鳞状细胞癌患者的II期试验
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E566-70. doi: 10.1002/hed.24041. Epub 2015 Jul 6.

引用本文的文献

1
Radiotherapy and Systemic Therapies: Focus on Head and Neck Cancer.放射治疗与全身治疗：聚焦头颈癌
Cancers (Basel). 2023 Aug 24;15(17):4232. doi: 10.3390/cancers15174232.